NexDx Appoints Mary K. Crow, M.D. to Scientific Advisory Board

NexDx, Inc. (http://www.nexdx.com), a science driven molecular diagnostics company providing next generation products and services for personalized medicine in rheumatoid arthritis and other autoimmune diseases, announced today the appointment of internationally renowned physician and scientist Mary K. Crow, M.D. (http://bit.ly/O7h1mJ) to its Scientific Advisory Board

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

San Diego, CA (PRWEB) July 31, 2012

NexDx, Inc. (http://www.nexdx.com), a science driven molecular diagnostics company providing next generation products and services for personalized medicine in rheumatoid arthritis and other autoimmune diseases, announced today the appointment of internationally renowned physician and scientist Mary K. Crow, M.D. (http://bit.ly/O7h1mJ) to its Scientific Advisory Board.

“We are thrilled to welcome to our team Peggy Crow, a world class clinician, researcher, and leader in the field of systemic autoimmune diseases at the Hospital for Special Surgery, one of the top orthopedic and rheumatology hospitals in the world. Bringing her expertise to NexDx will help us realize our scientific goals in rheumatoid arthritis, as well as help expand our efforts in other autoimmune diseases,” said Jonathan Lim, M.D., co-founder, chairman and CEO of NexDx.

“I am enthusiastic about helping to advance the novel approaches that NexDx is applying to several of the most complex and challenging diseases in all of medicine,“ said Dr. Crow.

Dr. Crow is Physician-in-Chief and Chair of the Division of Rheumatology at the Hospital for Special Surgery (HSS) (http://www.hss.edu) in New York City. She is also the Director of the Autoimmunity and Inflammation Research Program and serves as Co-Director of the Mary Kirkland Center for Lupus Research at HSS.

At the Weill Cornell Medical College, also in New York City, Dr. Crow is Chief of the Division of Rheumatology in the Department of Medicine.

She is the past president of both the American College of Rheumatology and the prestigious Henry Kunkel Society for patient-oriented research, particularly in the fields of immunology and rheumatology.

Articles authored and co-authored by Dr. Crow have been published in several highly respected, peer-reviewed journals, including the New England Journal of Medicine, Genes and Immunity and Arthritis and Rheumatism.

About NexDx, Inc.:

NexDx, Inc., located in San Diego, California, is a science driven molecular diagnostics company providing next generation products and services for personalized medicine in rheumatoid arthritis and other autoimmune diseases.

The company, founded in August 2011 by Jonathan E. Lim, M.D. and Gary S. Firestein, M.D. (Professor of Medicine at UC San Diego), is a pioneer in the application of epigenomics and other next generation molecular approaches to the discovery, development, and commercialization of novel biomarkers and tests for diagnostic and therapeutic applications in autoimmune diseases.

The scientific discoveries that led to the founding of NexDx were published in July 2012 in the Annals of the Rheumatic Diseases (http://bit.ly/QOZ8Zr). The company recently announced the successful closing of a $2.1 million Series B financing led by City Hill Ventures, LLC (http://www.cityhillventures.com/) and a $500,000 capital term loan from Silicon Valley Bank (http://www.svb.com/). For more information, please visit: http://www.nexdx.com


Contact